GlobeNewswire Inc.··NaRein Therapeutics Raises $50M via IPO to Fund Pulmonary Fibrosis Trial
Rein Therapeutics prices $50M stock offering at $1.00 per share to fund LTI-03 Phase 2 trial for idiopathic pulmonary fibrosis, with cash runway extended through 2028.
RNTXclinical trialpublic offering